If you've ever noticed that your mental health symptoms seem to get significantly worse before your period — even when you're already managing a condition like depression, anxiety, or bipolar disorder — this editorial sheds light on why that happens and what can be done about it.
The authors describe a condition called premenstrual exacerbation (PME), which is different from PMDD. With PMDD, symptoms appear mainly in the days before your period and then lift once menstruation starts. With PME, you already have an ongoing mental health condition, but it gets noticeably worse during the luteal phase (the roughly two weeks between ovulation and your period). The key difference is that PME symptoms don't fully go away after your period — they're present all cycle long but become harder to manage premenstrually. The authors stress that PME is widely underrecognised, leading to misdiagnosis and inadequate treatment.
The piece explains the hormonal reasons behind this worsening. Oestrogen, which supports mood-regulating brain chemicals like serotonin and dopamine, drops sharply in the luteal phase. At the same time, fluctuations in a progesterone-related molecule called allopregnanolone can paradoxically increase anxiety and irritability instead of calming the brain as expected. For someone already living with a mental health condition, these shifts can tip the balance.
For management, the authors suggest several approaches: adjusting medication doses during the luteal phase (for example, a small supervised increase in antidepressant dose before your period), exploring certain hormonal contraceptives that stabilise hormone levels, psychoeducation and symptom tracking to identify cyclical patterns, and lifestyle measures like exercise and stress reduction. Importantly, the authors call for routine menstrual history-taking in psychiatric assessments so that cyclical worsening isn't missed. If you suspect your symptoms follow a monthly pattern, tracking them with a daily symptom diary and discussing the results with your healthcare provider could be a valuable first step.
Key findings
- PME is distinct from PMS and PMDD: women with PME experience mental illness throughout the entire menstrual cycle but with marked symptom worsening in the luteal phase, whereas PMS/PMDD symptoms are largely confined to the premenstrual period
- PME can exacerbate symptoms across multiple psychiatric disorders including major depressive disorder, bipolar disorder, ADHD, and schizophrenia, increasing risks such as suicidal ideation and functional impairment during the luteal phase
- The sharp decline in oestrogen during the luteal phase reduces serotonin and dopamine neurotransmission, while fluctuations in allopregnanolone (a progesterone metabolite) can paradoxically increase anxiety and mood instability via altered GABA receptor modulation
- A newer combined oral contraceptive pill containing 1.5 mg 17-beta oestradiol and 2.5 mg nomegestrol acetate shows promise for menstrual cycle-related mood disorders and may be useful as adjunctive treatment for PME
- SSRI dose self-titration across the menstrual cycle (increasing premenstrually, decreasing post-menstruation) under medical supervision is proposed as a management strategy for PME with comorbid depression, drawing on evidence from intermittent SSRI use in PMDD
- PMDD affects approximately 3.2% of the reproductive female population, while PMS affects about 80% of women
Methods, briefly
Guest editorial/expert opinion piece published in The British Journal of Psychiatry. No new data were collected or analysed. The authors synthesised existing literature and clinical experience to describe PME, its differentiation from PMS/PMDD, underlying hormonal mechanisms, and proposed management strategies.
Limitations to keep in mind
- No original data collected or analysed; arguments are based on narrative synthesis and clinical experience rather than systematic evidence review
- Management recommendations for PME (e.g., SSRI dose titration, adjunctive hormonal contraceptives) are largely extrapolated from PMDD evidence and clinical practice rather than PME-specific clinical trials
- The authors acknowledge significant gaps in knowledge of PME pathophysiology, diagnosis, and treatment, and call for future longitudinal studies
- Single authorship team from one centre (HER Centre Australia, Monash University)
The latest PMDD research, in your pocket
The app’s research feed is updated daily with newly published, peer-reviewed PMDD work - summarized in plain language.